Large-scale public data reuse to model immunotherapy response and resistance

Immune Checkpoint Blockade (ICB) have provided significant clinical benefits. However, only few patients show positive response to the ICB treatment. We have previously developed a biomarker named TIDE to predict response using gene expression data. The TIDE score is reflecting accurate patient response in many cancer types. Now, we are continuously integrating more ICB clinical trial data to our TIDE database, which will be used to studying and evaluating more biomarker that can benefit the ICB patients and cancer immunology.